Xenon Pharmaceuticals (XENE) Net Equity Issued and Repurchased (2013 - 2023)

Xenon Pharmaceuticals (XENE) has 9 years of Net Equity Issued and Repurchased data on file, last reported at $29.5 million in Q3 2023.

• On a quarterly basis, Net Equity Issued and Repurchased changed N/A year-over-year to $29.5 million in Q3 2023; TTM through Sep 2023 was $37.4 million, a N/A change from a year earlier, with the FY2020 full-year figure at $102.5 million, up 273.98% from the prior year.
• Net Equity Issued and Repurchased for Q3 2023 stood at $29.5 million, up from $7.9 million in the prior quarter.
• Over the last five years, Net Equity Issued and Repurchased for XENE reached as high as $102.5 million in Q1 2020 and fell as low as $7.9 million in Q1 2022.
• Historically, Net Equity Issued and Repurchased has averaged $37.8 million across 4 years, with a median of $29.2 million in 2019.
• On a YoY basis, Net Equity Issued and Repurchased climbed as much as 249900.0% in 2019 and fell as far as 238.76% in 2019.
• Year by year, Net Equity Issued and Repurchased stood at $20.0 million in 2019, then jumped by 412.28% to $102.5 million in 2020, then slumped by 92.31% to $7.9 million in 2022, then soared by 274.66% to $29.5 million in 2023.
• Per Business Quant data, the three most recent Net Equity Issued and Repurchased figures were $29.5 million in Q3 2023, $7.9 million in Q1 2022, and $102.5 million in Q1 2020.